Haemonetics Corp.
- HAE · NYSE
- Surgical & Medical Instruments & Apparatus
- Boston, MA
- 3,009 employees
- CIK 0000313143
Updated from SEC filings through
Top things to know
Executives
- Chris Simon Haemonetics’ CEO 8-K, 2026-08-06
- Christopher Simon President & CEO 4, 2026-05-19
- James D’Arecca Executive Vice President, Chief Financial Officer 10-K, 2026-05-20
- Farris Maryanne Maunsell VP, Chief Accounting Officer 4, 2026-06-08
- Maryanne E. Farris Vice President, Chief Accounting Officer 10-K, 2026-05-20
- Frank Chan EVP, Chief Operating Officer 4, 2026-05-19
What leadership is saying
“Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
Haemonetics Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Boston, MA. It trades as HAE on NYSE. Revenue was $1.3B in the fiscal year ending March 28, 2026, -2.0% from the year before. It reported about 3,009 employees. Chris Simon is Haemonetics’ CEO.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $1.3B 10-K, 2026-05-20 | $1.4B 10-K, 2026-05-20 | $1.3B 10-K, 2026-05-20 | $1.2B 10-K, 2025-05-21 | $993M 10-K, 2024-05-20 |
| Operating income | $157M 10-K, 2026-05-20 | $222M 10-K, 2026-05-20 | $165M 10-K, 2026-05-20 | $156M 10-K, 2025-05-21 | $80.8M 10-K, 2024-05-20 |
| SG&A | $442M 10-K, 2026-05-20 | $437M 10-K, 2026-05-20 | $430M 10-K, 2026-05-20 | $377M 10-K, 2025-05-21 | $340M 10-K, 2024-05-20 |
| Net income | $97.3M 10-K, 2026-05-20 | $168M 10-K, 2026-05-20 | $118M 10-K, 2026-05-20 | $115M 10-K, 2025-05-21 | $43.4M 10-K, 2024-05-20 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Chris Simon President and Chief Executive Officer at Haemonetics | Haemonetics’ CEO | 8-K, 2026-08-06 |
| Christopher Simon | President & CEO | 4, 2026-05-19 |
| James C. D'Arecca | Named in proxy bio: Executive Vice President, Chief Financial Officer | DEF 14A, 2026-06-09 |
| James D’Arecca | Executive Vice President, Chief Financial Officer | 10-K, 2026-05-20 |
| Frank W. Chan | Named in proxy bio: Executive Vice President, Chief Operating Officer | DEF 14A, 2026-06-09 |
| Farris Maryanne Maunsell | VP, Chief Accounting Officer | 4, 2026-06-08 |
| Maryanne E. Farris | Vice President, Chief Accounting Officer | 10-K, 2026-05-20 |
| Frank Chan | EVP, Chief Operating Officer | 4, 2026-05-19 |
| Roy Galvin | EVP, Chief Commercial Officer | 4, 2026-05-19 |
| Laurie A. Miller SVP and Chief Human Resources Officer at Haemonetics | SVP, Human Resources | 4, 2026-06-08 |
| Michelle L. Basil EVP and General Counsel at Haemonetics | EVP and General Counsel | 4, 2026-05-19 |
| Christopher A. Simon | director | 8-K, 2026-07-28 |
| Claire Pomeroy | director | 8-K, 2026-07-28 |
| Diane M. Bryant | director | 8-K, 2026-07-28 |
| Ellen M. Zane | director | 8-K, 2026-07-28 |
| Lloyd E. Johnson | director | 8-K, 2026-07-28 |
What Haemonetics Corp does
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation.
Shares and governance
| Shares outstanding | 45.5 million (as of October 30, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $2.2B (as of September 27, 2025) | 10-K, May 20, 2026 |
| Reportable segments | 2 (period ending September 26, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting March 28, 2026 (filed June 9, 2026) | DEF 14A, June 9, 2026 |
| Auditor | Ernst & Young LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 10, 2025 | Mark W. Kroll Director | Buy | 1,400 | $99K | Form 4, November 12, 2025 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-08
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-18
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-28
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-05
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-01
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-03
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-12
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Haemonetics Corp
- What does Haemonetics Corp do?
- In its own words, from Item 1 of its 10-K: "Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation."
- What is Haemonetics Corp's revenue?
- $1.3B for the fiscal year ending March 28, 2026, from its 10-K filed May 20, 2026.
- Is Haemonetics Corp profitable?
- Haemonetics Corp reported net income of $97.3M for the fiscal year ending March 28, 2026.
- How many employees does Haemonetics Corp have?
- About 3,009 as of March 28, 2026, as stated in its annual report.
- Who is the CEO of Haemonetics Corp?
- Chris Simon, Haemonetics’ CEO, as named in a 8-K filed August 6, 2026.
- Who is the CFO of Haemonetics Corp?
- James D’Arecca, Executive Vice President, Chief Financial Officer, as named in a 10-K filed May 20, 2026.
- Where is Haemonetics Corp headquartered?
- Boston, MA.
- What is Haemonetics Corp's stock ticker?
- HAE on NYSE.
- What industry is Haemonetics Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Haemonetics Corp's website?
- haemonetics.com.
- When does Haemonetics Corp report earnings next?
- February 4, 2027. Source: estimate_8k_pattern.
- Is Haemonetics Corp a public company?
- Yes. Haemonetics Corp files with the SEC under CIK 0000313143 and trades as HAE.
- Who audits Haemonetics Corp?
- Ernst & Young LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Haemonetics Corp are outstanding?
- 45.5 million shares as of October 30, 2026, from its 10-Q filed November 5, 2026.
- What is Haemonetics Corp's public float?
- $2.2B as of September 27, 2025, as reported on the cover of its 10-K filed May 20, 2026.
- How many business segments does Haemonetics Corp report?
- 2 reportable segments for the period ending September 26, 2026, from its 10-Q filed November 5, 2026.
- When is Haemonetics Corp's annual shareholder meeting?
- March 28, 2026, per its proxy statement (DEF 14A) filed June 9, 2026.
- Have Haemonetics Corp insiders traded stock recently?
- Since November 10, 2025, officers and directors reported 0 open-market sales and 1 purchase worth about $99K on Forms 4 and 5. The most recent: Mark W. Kroll (Director) bought 1,400 shares on November 10, 2025.